Braxia Scientific Corp. (CSE: BRAX) saw its ketamine treatments rise by 26% and revenue increase by 27% over the year ending March 31, 2023, but financial statements indicate that the company’s ability to continue its operations could be in jeopardy. Braxia, which recently completed dosing in its phase 2 psilocybin …

Ontario-based mushroom maker Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) reported a decent boost in both revenue and gross profit for its fiscal year ending March 31, 2023. The company, known for its premium brand of psilocybin truffles sold in the Netherlands’ legal, recreational market, saw its revenue rise …